Upadacitinib在克罗恩病患者中30个月以上有效且耐受良好:CELEST扩展研究
CELEST开放标签扩展研究纳入107例完成52周CELEST研究的克罗恩病患者,评估upadacitinib长期疗效与安全性。第30个月时临床缓解2.8/1.0在各组维持(15 mg组61%、30 mg组54%、剂量升级组55%),第24个月内镜应答维持(分别为68%、67%、40%)。30 mg组不良事件、严重不良事件、感染等发生率高于15 mg组。
要点
- 第30个月临床缓解2.8/1.0在15 mg组为61%、30 mg组为54%、剂量升级组为55%。
- 第24个月内镜应答在15 mg组为68%、30 mg组为67%、剂量升级组为40%。
- 30 mg组的不良事件、严重不良事件、导致停药的不良事件、感染、严重感染、带状疱疹和肌酸磷酸激酶升高发生率高于15 mg组。
核心结论
- 接受upadacitinib治疗的克罗恩病患者在30个月时观察到持续长期获益,至第24个月内镜进一步改善。
- 30个月安全性特征与upadacitinib已知安全性特征一致。
研究设计与样本
- 为II期双盲随机试验的开放标签扩展(OLE)研究。
- 共107例完成52周CELEST研究的患者进入CELEST开放标签扩展研究。
主要发现
- 第0周至第30个月,所有组的临床缓解2.8/1.0比例维持(第30个月:15 mg组61%、30 mg组54%、剂量升级组55%)。
- 所有组的内镜应答维持(第24个月:15 mg组68%、30 mg组67%、剂量升级组40%)。
- 30 mg组的不良事件、严重不良事件、导致停药的不良事件、感染、严重感染、带状疱疹和肌酸磷酸激酶升高发生率高于15 mg组。
关键数值与推荐
- 完成52周CELEST研究后,曾接受即释upadacitinib 3、6或12 mg每日两次或24 mg每日一次的患者,在CELEST开放标签扩展研究中接受缓释upadacitinib 15 mg每日一次。
- 曾接受即释upadacitinib 12或24 mg每日两次作为挽救治疗的患者,接受缓释upadacitinib 30 mg每日一次。
- 在CELEST开放标签扩展研究中起始upadacitinib 15 mg每日一次的患者,若在第4周或之后失去应答,剂量升级至upadacitinib 30 mg每日一次(剂量升级组)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The long-term efficacy and safety of upadacitinib was evaluated in an open-label extension (OLE) of a phase II, double-blind, randomized trial of patients with Crohn's disease. METHODS: Patients who completed the 52-week study (CELEST) received upadacitinib in the CELEST OLE as follows: those who had received immediate-release upadacitinib 3, 6, or 12 mg twice daily or 24 mg once daily (QD) received extended-release upadacitinib 15 mg QD and those who had received immediate-release upadacitinib 12 or 24 mg twice daily as rescue therapy received extended-release upadacitinib 30 mg QD. If any patient initiating upadacitinib 15 mg QD in CELEST OLE lost response at or after week 4, the dose was escalated to upadacitinib 30 mg QD (dose-escalated group). Clinical, endoscopic, inflammatory and quality-of-life measures were assessed. RESULTS: A total of 107 CELEST study completers entered CELEST OLE. The proportion of patients with clinical remission 2.8/1.0 was maintained between week 0 and month 30 in all groups (month 30: 15 mg, 61%; 30 mg, 54%; dose-escalation, 55%). Endoscopic response was maintained in all groups (month 24: 68%, 67%, and 40%, respectively). The rates of adverse events (AEs), serious AEs, AEs leading to discontinuation, infections, serious infections, herpes zoster, and creatine phosphokinase elevation were higher with upadacitinib 30 mg vs 15 mg. CONCLUSION: Sustained long-term benefit at 30 months and further endoscopic improvements to month 24 were observed in patients with Crohn's disease receiving upadacitinib. Safety over 30 months was consistent with the known safety profile of upadacitinib. CLINICALTRIALS: gov ID no: NCT02782663.
引用
- D'Haens G, Panés J, Louis E, et al. Upadacitinib Was Efficacious and Well-tolerated Over 30 Months in Patients With Crohn's Disease in the CELEST Extension Study. Clin Gastroenterol Hepatol. 2021. PMID: 34968730. doi:10.1016/j.cgh.2021.12.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。